Why the study?
Does type 2 diabetes and glycemic control affect platelet reactivity post-clopidogrel therapy in patients undergoing coronary stent implantation?
Population
90 patients (56 with type 2 diabetes and 34 nondiabetic) undergoing coronary stent implantation (PCI)
Comparison
Clopidogrel administration vs Nondiabetic patients receiving clopidogrel
Design
Cohort
Authors
Loading...
Elevated post-clopidogrel reactivity in diabetes may increase ischemic risk after PCI; leaves open whether glycemic control improves platelet response.
Does type 2 diabetes and glycemic control affect platelet reactivity post-clopidogrel therapy in patients undergoing coronary stent implantation?
Type 2 diabetes and poor glycemic control are associated with higher post-clopidogrel platelet reactivity, which increases the risk of ischemic events after PCI.
Saad et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: